内科

目的探讨丁苯酞联合神经节苷脂治疗急性脑梗死静脉溶栓治疗患者的临床效果及对神经功能的影响。方法将2016年3月至2019年3月我院收治的急性脑梗死静脉溶栓治疗患者138例随机分为对照组和观察组，每组69例。在基础治疗的前提下，对照组患者使用神经节苷脂治疗，观察组患者使用丁苯酞联合神经节苷脂治疗，连续治疗14 d。比较两组患者的临床疗效，比较两组患者治疗前后的凝血因子水平、神经功能缺损评分（NIHSS评分）、日常生活能力评分（Barthel指数，BI）及不良反应发生情况。结果观察组患者的临床疗效优于对照组，治疗总有效率（92.75%）显著高于对照组（79.71%），差异有统计学意义（P＜0.05）。治疗14 d后，观察组患者的凝血酶Ⅲ（ATⅢ）水平显著高于对照组，D-二聚体（DD）、纤维蛋白原（FIB）、血小板聚集率（PAG）显著低于对照组，差异有统计学意义（P＜0.05）；观察组患者的BI评分显著高于对照组，NIHSS评分显著低于对照组，差异有统计学意义（P＜0.05）。治疗期间，两组患者均未出现明显的不良反应。结论丁苯酞联合神经节苷脂治疗，能显著提高急性脑梗死患者的临床治疗效果，改善神经功能，改善预后，治疗安全性高。

ObjectiveTo investigate the clinical effect of butylphthalide combined with ganglioside in the treatment of patients with intravenous thrombolysis for acute cerebral infarction and its effect on neurological function. MethodsA total of 138 patients with intravenous thrombolysis for acute cerebral infarction admitted to our hospital from March 2016 to March 2019 were randomly divided into control group and observation group, with 69 cases in each group. On the premise of basic treatment, ganglioside was employed to patients in the control group, whereas butylphthalide combined with ganglioside was performed to patients in the observation group, for fourteen-day continuous treatment. The clinical efficacy of patients was compared between the two groups. The pre- and post-treatment levels of coagulation factors, neurological deficit scores (NIHSS scores), daily life ability scores (Barthel index, BI), and the occurrence of adverse reactions were compared between the two groups. ResultsThe clinical efficacy of the observation group was superior to that of the control group. The total effective rate (92.75%) was significantly higher than that of the control group (79.71%), and the difference was statistically significant (P＜0.05). After 14 days of treatment, the level of thrombin III (AT Ⅲ) in the observation group was significantly higher than that in the control group, and D-dimer (DD), fibrinogen (FIB), and platelet aggregation rate (PAG) were significantly lower than those in the control group, with the statistically significant differences (P＜0.05). Compared to the control group, the observation group obtained a higher BI score, lower NIHSS score, with the statistically significant differences (P＜0.05). There were no obvious adverse reactions in both groups during the treatment period. ConclusionThe treatment of butylphthalide combined with ganglioside can prominently improve the clinical efficacy in patients with acute cerebral infarction, improve neurological function and prognosis, and thus the treatment is highly safe.